Critical Care & Emergencies (all articles)
[Preprint] Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: An international collaborative meta-analysis of randomized trials
20 Sep, 2020 | 21:42h | UTC
Commentary on Twitter
This meta-analysis of 7,913 patients from 26 RCTs (16 unpublished) found no mortality benefit to #hydroxychloroquine or chloroquine in COVID19
Combined summary OR for all-cause mortality for HCQ 1.08, 95%CI 0.99-1.18
Confirms HCQ does not help, may harmhttps://t.co/4o9bXkOo5Q pic.twitter.com/QG1XMzN0da
— Ilan Schwartz is on🦋 (@GermHunterMD) September 19, 2020
Severe COVID-19 infections—knowledge gained and remaining questions
20 Sep, 2020 | 21:43h | UTCSevere COVID-19 Infections—Knowledge Gained and Remaining Questions – JAMA Internal Medicine
Commentary on Twitter
Just out @JAMAInternalMed – our editorial on what we've learned about severe #Covid19 pneumonia so far and what challenges are still ahead. Honored and proud to have written this together with Carolyn Calfee and Dan Brodie. https://t.co/rmVjUWNyvM
— Lieuwe Bos – Acute Pulmonary Medicine (@Acute_Pulmo_Med) September 18, 2020
Comparison of published guidelines for management of coagulopathy and thrombosis in critically ill patients with COVID 19
20 Sep, 2020 | 21:30h | UTC
Editorial: Convalescent plasma for Covid-19
20 Sep, 2020 | 21:29h | UTCConvalescent plasma for covid-19 – The BMJ
Commentary on Twitter
Last month the US FDA authorised the emergency use of convalescent plasma for hospital patients with covid-19. What evidence underpinned the FDA’s controversial decision? And will the authorisation make it more difficult to recruit participants for RCTS? https://t.co/PMO13J2IOq
— The BMJ (@bmj_latest) September 19, 2020
Pulmonary embolism in patients with coronavirus disease-2019 (COVID-19) pneumonia: A narrative review
18 Sep, 2020 | 09:39h | UTC
The pooled prevalence of pulmonary embolism in patients with COVID-19
18 Sep, 2020 | 09:37h | UTCThe pooled prevalence of pulmonary embolism in patients with COVID-19 – Intensive Care Medicine
Commentary on Twitter
Pulmonary embolism in #COVID19, be careful! quantitative meta-analysis ->
pooled prevalence in pts undergoing #PE diagnosis 28%
higher pooled prevalence in pts admitted to #ICU vs those admitted to non-ICU: 19 vs 9%
Open access @yourICM #COVIDFOAM #FOAMcc https://t.co/dUqKAVoeCV pic.twitter.com/fvmQnTlv1M— Intensive Care Medicine (@yourICM) September 15, 2020
How COVID-19 can damage the brain
17 Sep, 2020 | 09:36h | UTCHow COVID-19 can damage the brain – Nature
Commentary on Twitter
How COVID-19 can damage the brain https://t.co/uQUS5y9AXU 125 people in the United Kingdom with COVID-19 who had neurological or psychiatric effects. 62% had strokes and haemorrhages, and 31% had altered mental states, such as confusion or prolonged unconsciousness.
— Carlos del Rio (@CarlosdelRio7) September 16, 2020
[Press release – not published yet] Eli Lilly reports first, promising results for an antibody against COVID-19
17 Sep, 2020 | 09:28h | UTCEli Lilly reports first, promising results for an antibody against COVID-19 – Science
Press release: Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting
CDC Study: Characteristics and maternal and birth outcomes of hospitalized pregnant women with laboratory-confirmed COVID-19
17 Sep, 2020 | 09:29h | UTC
Commentary on Twitter
.@CDCMMWR report looking at almost 600 hospitalized pregnant women with #COVID19 found that pregnant women can have severe illness and poor birth outcomes, such as the mother requiring intensive care, pregnancy loss, and preterm birth. Learn more: https://t.co/g7WsFWJdDs. pic.twitter.com/Ve0dnGNTDM
— CDC (@CDCgov) September 16, 2020
Multisystem effects of COVID-19: A concise review for practitioners
16 Sep, 2020 | 09:14h | UTCMultisystem effects of COVID-19: A concise review for practitioners – Postgraduate Medicine
COVID-19: Guidance on palliative care from a European Respiratory Society international task force
16 Sep, 2020 | 09:16h | UTC
AHA Scientific Statement: Drug-induced arrhythmias
16 Sep, 2020 | 08:50h | UTCDrug-Induced Arrhythmias: A Scientific Statement From the American Heart Association – Circulation
Commentary: Drug Proarrhythmia
Top Things to Know: Drug-Induced Arrhythmias
News Release: Identifying, preventing and managing heart rhythm side effects of medicines
Cohort study: Intra-arrest transport vs. continued on-scene resuscitation in patients with out-of-hospital cardiac arrest
16 Sep, 2020 | 08:48h | UTCAssociation of Intra-arrest Transport vs Continued On-Scene Resuscitation With Survival to Hospital Discharge Among Patients With Out-of-Hospital Cardiac Arrest – JAMA (free for a limited period)
Editorial: Challenging the “Scoop and Run” Model for Management of Out-of-Hospital Cardiac Arrest (free for a limited period)
Commentary: For Cardiac Arrest, Too-Hasty Transport Gets in the Way of Good CPR – MedPage Today (free registration required)
Commentary on Twitter
So "Stay and Play" beats "Scoop and Run", at least for cardiac arrest. Intra-arrest Transport vs Continued On-Scene Resuscitation and Survival in Patients With Out-of-Hospital… https://t.co/cjazp4jn1e via @JAMA_current part of @JAMANetwork
— Matthew Martin, MD, FACS, McRIB (@docmartin22) September 16, 2020
NIH launches two trials to test blood thinners in COVID-19 patients
15 Sep, 2020 | 08:56h | UTCNIH launches two trials to test blood thinners in COVID-19 patients – Reuters
Systematic review: Prediction of poor neurological outcome in comatose survivors of cardiac arrest
15 Sep, 2020 | 08:40h | UTCEditorial: ERC‑ESICM guidelines for prognostication after cardiac arrest: time for an update
Commentary on Twitter
Poor neuro-outcome in comatose survivors of CA ->
clinical exam, biomarkers, EEG, neuroimaging reliable predictors within 1st week from ROSC; low/0% FPR but most low sensitivity & risk of bias/confounders: no certainty, multimodal approach prudent #FOAMres https://t.co/GjQNoT1L49 pic.twitter.com/WUZofIslZx— Intensive Care Medicine (@yourICM) September 11, 2020
State of the art review: Hepatorenal syndrome
15 Sep, 2020 | 08:41h | UTCHepatorenal syndrome: pathophysiology, diagnosis, and management – The BMJ (free for a limited period)
Commentary on Twitter
Hepatorenal syndrome is a serious complication of cirrhosis that is associated with high morbidity and mortality. This review discusses its definition, pathophysiology, diagnosis, and management of hepatorenal syndromehttps://t.co/m9QnH6n2lJ
— The BMJ (@bmj_latest) September 14, 2020
Updated meta-analysis: Drug treatments for Covid-19
14 Sep, 2020 | 01:04h | UTCDrug treatments for covid-19: living systematic review and network meta-analysis – The BMJ
Commentary on Twitter
https://twitter.com/RSiemieniuk/status/1304447644438327297
Meta-analysis: PEEP-induced recruited lung volume measured by volume-pressure curves in ARDS
14 Sep, 2020 | 00:51h | UTC
Commentary on Twitter
PEEP-induced recruited lung volume measured
by VP curves in #ARDS, systematic review: after PEEP increment most pts are recruiters (Vrec > 150ml, 74%). #ICU mortality no significantly different between recruiters/non but evidence very low/publication bias https://t.co/fgyAscoWCf pic.twitter.com/WD02pMycWr— Intensive Care Medicine (@yourICM) September 12, 2020
Cochrane evidence on COVID-19: a round-up
11 Sep, 2020 | 01:47h | UTCCochrane evidence on COVID-19: a round-up – Evidently Cochrane
Acute kidney injury in hospitalized patients with and without COVID-19: A comparison study
11 Sep, 2020 | 01:44h | UTCCommentary: Deaths Sky High in Hospitalized COVID Patients With Kidney Injury – Medscape AND Acute Kidney Injury in COVID-19 Patients – Physician’s Weekly
Commentary on Twitter
Via @JASN_News: patients with COVID-19 had sig. higher incidence of AKI, more likely to require RRT, ICU, & ventilation cf. pts w/o COVID-19 or historical controls. https://t.co/cS2n0TH6we
— Nature Reviews Urology (@NatRevUrol) September 4, 2020
COVID-19 and pneumothorax: A multicenter retrospective case series
11 Sep, 2020 | 01:39h | UTCCOVID-19 and Pneumothorax: A Multicentre Retrospective Case Series – European Respiratory Journal
Commentary: Another possible COVID complication: ‘Punctured lung’ – CIDRAP
Preliminary randomized trial evaluated recombinant human granulocyte colony–stimulating factor for patients with COVID-19 and lymphopenia
11 Sep, 2020 | 01:36h | UTCInvited Commentary: Immune Stimulation With Recombinant Human Granulocyte Colony–Stimulating Factor for Coronavirus Disease 2019 (COVID-19)—Beware of Blind Spots
Commentary on Twitter
Preliminary findings from a randomized clinical trial suggest that rhG-CSF treatment should be studied in larger trials and in a broader range of patients with #COVID19 https://t.co/SjsoWOkEXg
— JAMA Internal Medicine (@JAMAInternalMed) September 10, 2020
Bacterial and fungal superinfections in critically ill patients with COVID-19
11 Sep, 2020 | 01:28h | UTC
Commentary on Twitter
Bacterial/fungal superinfections in critically ill #COVID19 pts: true prevalence still elusive. Underestimation of late superinfection risk may occur in #ICU; confounding factors also hamper identification of most frequently associated bacteria #COVIDFOAM https://t.co/iDAyOwYekr pic.twitter.com/Z7N4V7tc7q
— Intensive Care Medicine (@yourICM) September 10, 2020
New easy-to-use score for predicting risk of death in patients hospitalized with Covid-19
10 Sep, 2020 | 09:51h | UTCCommentaries: Discovery of four COVID-19 risk groups helps guide treatment – University of Edinburgh AND Expert reaction to a study looking at predicting the risk of death in hospitalised COVID-19 patients – Science Media Centre
Commentary on Twitter
NEW #BMJResearch finds that an easy-to-use score for predicting risk of death in adult patients admitted to hospital with #COVID19 outperforms existing scores and can be used to support treatment decisions @ProfCalumSemple @ISARIC1
https://t.co/2J9S3mqG5h— The BMJ (@bmj_latest) September 10, 2020
Clinical outcomes in young adults hospitalized with COVID-19
10 Sep, 2020 | 09:49h | UTCClinical Outcomes in Young US Adults Hospitalized With COVID-19 – JAMA Internal Medicine
Editorial: Regardless of Age, Obesity and Hypertension Increase Risks With COVID-19
Commentary: Obesity greatest risk factor for young adults with COVID-19 – MedicalXpress
Commentary on Twitter
18 to 34 years old #COVID19 hospitalized outcomes:
✔️21% intensive care,
✔️10% mechanical ventilation
✔️2.7% died.
✔️Morbid obesity, hypertension & diabetes associated with⬆️risks of adverse events.
✔️+ ½ requiring hospitalization: Black or Hispanic⚓️https://t.co/kcs2cery7s pic.twitter.com/ASVB943Bhc
— Medtorek (@Medtorek) September 9, 2020